Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin vs Baclofen for Early Post-stroke Spasticity Treatment
NCT02462317Phase 4Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Apr 2015
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of lanbotulinumtoxin-A in Spasticity (3 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Fugl-Meyer Assessment at 3 months. Started Apr 2015; status: completed.
02
Drugs
lanbotulinumtoxin-A
03
Conditions
Spasticity
Beyond the preview
Go deeper on NCT02462317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462317.